X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.98−0.11 (-3.56%)
Close on Nov 18, 2026Market cap $295.46MP/E –Yield –
X4 Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
X4 Pharmaceuticals's net income for the twelve months ending Sep 30, 2026 was -$80.52M. For fiscal 2025 it was -$79.20M. The highest annual figure on record is -$21.99M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$79.20M | – |
| FY2024 | Dec 31, 2024 | -$37.45M | – |
| FY2023 | Dec 31, 2023 | -$101.17M | – |
| FY2022 | Dec 31, 2022 | -$93.87M | – |
| FY2021 | Dec 31, 2021 | -$88.70M | – |
| FY2020 | Dec 31, 2020 | -$62.13M | – |
| FY2019 | Dec 31, 2019 | -$52.81M | – |
| FY2018 | Dec 31, 2018 | -$33.29M | – |
| FY2017 | Dec 31, 2017 | -$21.99M | – |
| FY2016 | Dec 31, 2016 | -$22.98M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.20M | – |
| Q2 FY2026 | Jun 30, 2026 | -$16.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.24M | -7277.7% |
| Q4 FY2025 | Dec 31, 2025 | -$23.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.74M | -128.3% |
| Q1 FY2025 | Mar 31, 2025 | $282.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.70M | – |
| Q2 FY2024 | Jun 30, 2024 | $90.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.97M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.18M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.71M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.87M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.03M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.37M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.19M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.71M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.39M | – |
See a number that looks wrong?